AKBA
NASDAQ · Biotechnology
Akebia Therapeutics Inc
$1.41
+0.05 (+3.68%)
Open$1.40
Previous Close$1.36
Day High$1.42
Day Low$1.38
52W High$4.08
52W Low$1.14
Volume—
Avg Volume2.77M
Market Cap383.07M
P/E Ratio—
EPS$-0.02
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,556.0% upside
Current
$1.41
$1.41
Target
$37.45
$37.45
$22.27
$37.45 avg
$46.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 244.34M | 262.39M | 65.59M |
| Net Income | -5,533,194 | -5,347,803 | -3,878,355 |
| Profit Margin | -2.3% | -2.2% | -5.9% |
| EBITDA | 21.18M | 21.60M | -4,128,349 |
| Free Cash Flow | — | — | -1,979,346 |
| Rev Growth | -6.9% | -6.9% | +11.6% |
| Debt/Equity | 5.94 | 5.94 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |